Eli Lilly (LLY): FY25 Q2 earnings call, Aug 7, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Aug 7, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
17 matches for “Mounjaro”; 5 quoted, at least 25 words apart.
…Q2 2024, driven by our key products. These include Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound. In the U.S., we continue the robust uptake…
…type 2 diabetes incretin market. Outside the U.S., we continue to launch Mounjaro in new countries. These include Mexico and Brazil, most recently. We have…
…increased 38% in Q2 driven by strong volume growth of Zepbound and Mounjaro, partially offset by an 8% decline in price. In Europe, revenue grew…
…constant currency, driven primarily by stocking in the base period related to Mounjaro launches in new markets. This impact was largely offset by volume growth…
…year following the recent CHMP positive opinion. Finally, moving to cardiometabolic drugs. Mounjaro and Zepbound both delivered impressive performance. Mounjaro posted $5.2 billion of global…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-08-07:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-08-07:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP